These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 9547332)

  • 1. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity.
    Schneider P; Holler N; Bodmer JL; Hahne M; Frei K; Fontana A; Tschopp J
    J Exp Med; 1998 Apr; 187(8):1205-13. PubMed ID: 9547332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of death receptor pathways in oncology.
    de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
    Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand.
    Knox PG; Milner AE; Green NK; Eliopoulos AG; Young LS
    J Immunol; 2003 Jan; 170(2):677-85. PubMed ID: 12517928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex.
    Holler N; Tardivel A; Kovacsovics-Bankowski M; Hertig S; Gaide O; Martinon F; Tinel A; Deperthes D; Calderara S; Schulthess T; Engel J; Schneider P; Tschopp J
    Mol Cell Biol; 2003 Feb; 23(4):1428-40. PubMed ID: 12556501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively.
    Kajiwara K; Saito A; Ogata S; Tanihara M
    Biochim Biophys Acta; 2004 Jun; 1699(1-2):131-7. PubMed ID: 15158720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.
    Pelli N; Floreani A; Torre F; Delfino A; Baragiotta A; Contini P; Basso M; Picciotto A
    Clin Exp Immunol; 2007 Apr; 148(1):85-9. PubMed ID: 17302732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
    Dupont PJ; Warrens AN
    Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
    Nakae H; Narita K; Endo S
    J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis.
    Powell WC; Fingleton B; Wilson CL; Boothby M; Matrisian LM
    Curr Biol; 1999 Dec 16-30; 9(24):1441-7. PubMed ID: 10607586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.
    Schneider P; Bodmer JL; Holler N; Mattmann C; Scuderi P; Terskikh A; Peitsch MC; Tschopp J
    J Biol Chem; 1997 Jul; 272(30):18827-33. PubMed ID: 9228058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha and Fas/Fas ligand signaling pathways in chronic spontaneous urticaria.
    Grzanka R; Damasiewicz-Bodzek A; Kasperska-Zajac A
    Allergy Asthma Clin Immunol; 2019; 15():15. PubMed ID: 30911316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand.
    Vargo-Gogola T; Crawford HC; Fingleton B; Matrisian LM
    Arch Biochem Biophys; 2002 Dec; 408(2):155-61. PubMed ID: 12464266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
    Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
    Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
    Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
    Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
    Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.
    Poulaki V; Mitsiades CS; McMullan C; Fanourakis G; Negri J; Goudopoulou A; Halikias IX; Voutsinas G; Tseleni-Balafouta S; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):358-66. PubMed ID: 15623796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
    Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
    Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the functional soluble form of human fas ligand in activated lymphocytes.
    Tanaka M; Suda T; Takahashi T; Nagata S
    EMBO J; 1995 Mar; 14(6):1129-35. PubMed ID: 7536672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis.
    Hashimoto H; Tanaka M; Suda T; Tomita T; Hayashida K; Takeuchi E; Kaneko M; Takano H; Nagata S; Ochi T
    Arthritis Rheum; 1998 Apr; 41(4):657-62. PubMed ID: 9550474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.